FDA Grants AP Status for Oxcarbazepine Supplement by Chartwell RX
The FDA has granted Abbreviated Approval (AP) status for the oxcarbazepine supplement submitted by Chartwell RX.
Asset / Drug
Drug and asset intelligence for Oxcarbazepine with 16 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
The FDA has granted approval for the ANDA209020 application for OXCARBAZEPINE submitted by MSN.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.